This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mulvey, T. M. Search for Related Content PubMed Articles by Mulvey, T. M.

Preserving Evidence-Based Oncology: We Can't Jeopardize Clinical Trials

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Therese M. Mulvey, MD

Perhaps more than any other medical specialty, oncology relies on an evidence-based approach to treatment. If we are to maintain our commitment to evidence as the guide for treatment, we should be concerned about several recent trends.

Most notably, my attention has been drawn to a recent decision of the U.S. Court of Appeals in Washington, DC, in a suit brought against the US Food and Drug Administration (FDA) by a group called the Abigail Alliance for Better Access to Developmental Drugs. In a May 2, 2006, decision, the Court of Appeals ruled that a terminally . . . [Click for More]

This article has been cited by other articles:

				Medicare's Coverage With Evidence Development: A Policy-Making Tool in Evolution J. Oncol. Pract, November 1, 2007; 3(6): 296 - 301. [Full Text] [PDF]